A randomized phase II trial of hydroxyurea ± imatinib in the treatment of recurrent or progressive meningiomas

被引：0
|
作者：
Mazza, E. [1 ]
Reni, M. [1 ]
Lombardi, G. [2 ]
Eoli, M. [3 ]
Franceschi, E. [4 ]
Faedi, M. [5 ]
Fugazza, C. [1 ]
Maggiora, P. [1 ]
Finocchiaro, G. [3 ]
Brandes, A. [4 ]
机构：
[1] Hosp San Raffaele, I-20132 Milan, Italy
[2] Ist Oncol Veneto IRCCS, Padua, Italy
[3] Ist Neurol C Besta, Unit Mol Neurooncol, Milan, Italy
[4] Bellaria Maggiore Hosp, Bologna, Italy
[5] Osped Gen Provinciale M Bufalini, Cesena, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3356
引用
收藏
页码：S791 / S791
页数：1
相关论文
共 50 条
  • [41] Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma
    Kaley, Thomas J.
    Wen, Patrick
    Schiff, David
    Ligon, Keith
    Haider, Sam
    Karimi, Sasan
    Lassman, Andrew B.
    Nolan, Craig P.
    DeAngelis, Lisa M.
    Gavrilovic, Igor
    Norden, Andrew
    Drappatz, Jan
    Lee, Eudocia Quant
    Purow, Benjamin
    Plotkin, Scott R.
    Batchelor, Tracy
    Abrey, Lauren E.
    Omura, Antonio
    [J]. NEURO-ONCOLOGY, 2015, 17 (01) : 116 - 121
  • [42] TREATMENT OF RECURRENT MENINGIOMAS WITH IMATINIB MESYLATE: A SINGLE-INSTITUTION EXPERIENCE
    Horak, P.
    Woehrer, A.
    Hassler, M.
    Hainfellner, J.
    Marosi, C.
    [J]. NEURO-ONCOLOGY, 2010, 12 : 55 - 55
  • [43] Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis
    Horak, Peter
    Woehrer, Adelheid
    Hassler, Marco
    Hainfellner, Johannes
    Preusser, Matthias
    Marosi, Christine
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2012, 109 (02) : 323 - 330
  • [44] Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis
    Peter Horak
    Adelheid Wöhrer
    Marco Hassler
    Johannes Hainfellner
    Matthias Preusser
    Christine Marosi
    [J]. Journal of Neuro-Oncology, 2012, 109 : 323 - 330
  • [45] VANDETANIB, IMATINIB MESYLATE, AND HYDROXYUREA FOR RECURRENT MALIGNANT GLIOMA: A PHASE I STUDY
    Desjardins, Annick
    Vredenburgh, James J.
    Gururangan, Sridharan
    Peters, Katherine B.
    Friedman, Allan H.
    Friedman, Henry
    Reardon, David A.
    [J]. NEURO-ONCOLOGY, 2009, 11 (05) : 634 - 634
  • [46] PHASE I STUDY OF VANDETANIB, IMATINIB MESYLATE, AND HYDROXYUREA FOR RECURRENT MALIGNANT GLIOMA
    Reardon, David A.
    Vredenburgh, James. L.
    Desjardins, Annick
    Gururangan, Sridharan
    Peters, Katherine B.
    Boulton, Susan T.
    [J]. NEURO-ONCOLOGY, 2009, 11 (06) : 946 - 946
  • [47] Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma
    Reardon, David A.
    Desjardins, Annick
    Vredenburgh, James J.
    Herndon, James E., II
    Coan, April
    Gururangan, Sridharan
    Peters, Katherine B.
    McLendon, Roger
    Sathornsumetee, Sith
    Rich, Jeremy N.
    Lipp, Eric S.
    Janney, Dorothea
    Friedman, Henry S.
    [J]. CANCER, 2012, 118 (19) : 4759 - 4767
  • [48] Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma
    Kirkpatrick, J. P.
    Vredenburgh, J. J.
    Desjardins, A.
    Gururangan, S.
    Peters, K. B.
    Boulton, S. T.
    Friedman, A. H.
    Friedman, H. S.
    Reardon, D. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] Imatinib plus hydroxyurea in pretreated non-progressive glioblastorna (GBM) - A single center phase II study.
    Dresemann, G.
    Hosius, C.
    Nikolova, Z.
    Letvak, L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 78S - 78S
  • [50] Imatinib mesylate in the treatment of systemic mastocytosis, a phase I/II trial
    Droogendijk, HJ
    Kluin-Nelemans, JC
    van Daele, PLA
    [J]. BLOOD, 2004, 104 (11) : 424A - 424A
12345